Responses
Regular and Young Investigator Award Abstracts
Combination Immunotherapies
850 Interim results for phase 1b dose expansion of MTL-CEBPA in combination with pembrolizumab in patients with advanced solid tumour malignancies
Compose a Response to This Article
Other responses
No responses have been published for this article.